undamentalytics Newsletter
Sign in

Teva Pharmaceutical Industries LTD (TEVA) stock

Add to watchlist

Add holding +

NYSE: TEVA NYSE Pharmaceuticals Next results ~November 3, 2026

Teva Pharmaceutical Industries LTD is a US-listed company in the pharmaceuticals industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Model estimate per share

~$25

Valuation models combined (2)

Base case. Range ~$22–$27. Weighted average of 2 models (forward price-to-earnings vs peers, forward price-to-sales vs peers).

Price vs value

No Buy/Hold/Sell rating is issued: limited reported history: available models are shown without a Buy/Hold/Sell rating.

Teva Pharmaceutical Industries LTD valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders0 buying, 14 selling0 purchases and 58 sales by directors and officers, last 12 monthsInsider trades
  • Funds349 adding, 249 cuttingOf 66 active managers that changed their stake, 37 added; quarter to June 30, 2026Fund buyers and sellers

The Fundamentalytics view

Next results ~November 3, 2026 (estimated)

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

Nothing in Teva Pharmaceutical Industries LTD's latest figures clears our strength thresholds.

Things to watch

  • Insiders selling. 14 insiders sold $113M of stock over the past 365 days and none bought (61% under pre-set trading plans).

Price chart

  • 1 day-3.3%
  • 1 week+1.9%
  • 1 month+3.0%
  • This year+30.4%
  • 1 year+98.7%
  • 5 years+333.4%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Earnings

Last results
November 3, 2026
Next results (est.)
January 27, 2027

News & updates

Updated November 3, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Results
  2. Leadership
  3. Insider trade
  4. Agreement
  5. Announcement
  6. Announcement
  7. Announcement
  8. Results

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Teva Pharmaceutical Industries LTD valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: limited reported history: available models are shown without a Buy/Hold/Sell rating.

Valuation models

We value Teva Pharmaceutical Industries LTD as an operating company, with every model that fits that kind of business. Cost of equity 8.7%: the 10-year Treasury yield (4.9%) plus a beta of 0.84 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Growth cash-flow model Revenue for this year and next from analysts' consensus, then growth fading to 2.5%; the operating margin moving to profitable peers'; investment needed per dollar of growth from peers; reduced by a failure probability. For young or fast-growing companies. The starting margin is normalized to between -100% and 60%; net margin is a proxy when operating income is not tagged. Uses analysts' consensus estimates (third-party data), not our forecasts. — Does not apply: no revenue, margin or share count to start from
Forward price-to-earnings vs peers Next year's consensus earnings per share times peers' typical (harmonic-mean) forward price-to-earnings. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$27 ~$28–$57 Included
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: no twelve-month earnings or share count in the filings yet
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: no twelve-month earnings or share count in the filings yet
Forward price-to-sales vs peers Next year's consensus sales per share times peers' typical forward price-to-sales; only when earnings are negative. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$22 ~$19–$56 Included, half weight
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. — Does not apply: revenue and margins don't support a positive value
Combined value Weighted average of the models that apply: the primary model (growth cash-flow model) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. ~$25 ~$22–$27 2 models

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Teva Pharmaceutical Industries LTD with Pharmaceuticals in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 3, 2026, after the close. Analysts expect revenue of $4.2bn and EPS of $0.73 (range $0.60 to $0.89) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current $2.11 — $16.7bn −4%
Next $3.09 +47% $17.2bn +4%

How the EPS forecast has moved

In the last 30 days, 0 analysts raised Teva Pharmaceutical Industries LTD's forecast and 0 cut it.

Consensus EPS forecast Teva Pharmaceutical Industries LTD, last 90 days
$2.00 $2.50 $3.00 $3.50 30 days ago 7 days ago Now Current fiscal year, 30 days ago: $2.15 Current fiscal year, 7 days ago: $2.11 Current fiscal year, Now: $2.11 $2.11 Next fiscal year, 30 days ago: $3.05 Next fiscal year, 7 days ago: $3.09 Next fiscal year, Now: $3.09 $3.09

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
30 days ago $2.15$3.05
7 days ago $2.11$3.09
Now $2.11$3.09

Analyst recommendations

13 analysts, Oct 2026
Buy1292%
Hold18%
Sell00%

Monthly trend

  1. Oct 202648113
  2. Sep 20263418

Counts of recommendations published by analysts covering Teva Pharmaceutical Industries LTD, by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
2.4%
of tradable shares
Days to cover
4.4
at average volume
Short interest, 1 month
−11%
to October 15, 2026
Held by institutions
30%
of shares
Held by insiders
0.6%
of shares
Employees
31,173
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Recent prices are available. Older price history and the statistics that need it are being loaded in the background.

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
TEVA−17%+14%+15%+111%+42%+30%
Industry peers (median)−20%−52%−14%−2%+7%−14%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
TEVA25%50%58%67%58%64%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
TEVA−38%−34%−37%−13%−42%−22%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since November 2, 2015: 90% from December 24, 2015 to August 15, 2019. Getting back needed a 913% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$20.46 – $42.09
From 52-week high
−3.3%
vs 50-day average
+4.0%
vs 200-day average
+17.6%
Volatility (1 year)
39%
Beta vs S&P 500
0.70

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
8 up, 3 down
typical move ±10.0%
After a week
7 up, 4 down
typical move ±11.0%
After a month
9 up, 2 down
typical move ±15.1%
Results releasedNext dayS&P 500 next day5 days21 days
July 29, 2026 +11.8% +0.1% +9.6% +18.8%
April 29, 2026 +10.9% +1.0% +14.9% +11.7%
January 28, 2026 +1.7% −0.2% +7.5% +4.1%
January 12, 2026 +1.4% 0.0% −2.0% +7.2%
November 5, 2025 +19.6% −0.7% +26.2% +39.1%
July 30, 2025 −6.6% −0.5% −3.2% +9.1%
May 7, 2025 +12.1% +1.1% +4.8% +10.2%
January 29, 2025 −17.1% +0.1% −20.1% −23.5%
November 6, 2024 −6.8% +3.3% −9.7% −7.7%
July 31, 2024 +6.9% +0.2% +2.3% +14.1%
May 8, 2024 +14.7% +0.6% +20.3% +20.6%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Fundamentals

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms . Generated November 3, 2026. Definitions in our methodology.

Where the revenue comes from

Fiscal year to December 31, 2025
Segments
Line of business Revenue Share YoY
United States $9.2B 53.2% ▲ 14.3%
Europe $5B 29.2% ▼ 1.2%
International Markets $2.2B 12.5% ▼ 12.2%
Other Activities $870M 5.0% ▼ 7.8%
Products and services
Line of business Revenue Share YoY
Products $14.6B 84.6% ▲ 4.0%
Distribution Service $1.6B 9.0% ▼ 1.6%
Licenses $678M 3.9% ▲ 291.9%
Other $423M 2.5% ▼ 43.2%
Geography
Region Revenue YoY
United States $9.2B ▲ 14.3%
Europe $5B ▼ 1.2%

These categories overlap or exclude eliminations, so shares aren't shown.

From Teva Pharmaceutical Industries LTD's 10-K filed February 3, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Who owns it

Funds buying and selling
Reported value
$24.8B
Institutions reporting
672
Shares held vs prior quarter
▲ 8.8%
Positions opened / closed
75 / 54

Top buyers and sellers, Q2 2026: 349 institutions bought and 249 sold ; the biggest buyer was Meitav Investment House Ltd (+9.9M shares) and the biggest seller Lingotto Investment Management LLP (−7.6M). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Blackrock, Inc. $2.2B 63.9M 8.7% ▼ 1.9%
Harel Insurance Investments & Financial Services Ltd. $1.6B 48.1M 6.6% ▲ 4.7%
Phoenix Financial Ltd. $1.5B 42.9M 5.9% ▲ 0.4%
WCM Investment Management, LLC $1.4B 41.3M 5.5% ▲ 1.2%
Clal Insurance Enterprises Holdings Ltd $1.4B 40.6M 5.5% ▲ 5.6%
Menora Mivtachim Holdings Ltd. $1.4B 39.9M 5.4% ▲ 0.6%
Migdal Insurance & Financial Holdings Ltd. $1.3B 38.9M 5.3% ▲ 2.7%
Norges Bank $1.1B 32.3M 4.4% —
FMR LLC $1B 30.3M 4.1% ▼ 8.7%
Lingotto Investment Management LLP $685M 20.2M 2.8% ▼ 27.2%
State Street Corp $642M 18.9M 2.6% ▲ 6.4%
Rubric Capital Management LP $528M 15.6M 2.1% ▲ 2.1%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Teva Pharmaceutical Industries LTD's complete shareholder register. Values are as reported by the filers ; 3 inconsistently scaled filing rows were excluded.

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $113M 58 trades by 14 insiders · 61% under pre-set plans
Net ▼ $113M net selling
Insider Date Trade Shares Price Value
Mignone Roberto Director September 18, 2026 Sell 367,600 $39.06 $14.4M
Savage Brian Interim Chief Legal Officer September 18, 2026 Sell 4,503 $38.69 $174,221
Savage Brian Interim Chief Legal Officer September 18, 2026 Sell 2,525 $39.15 $98,854
Savage Brian Interim Chief Legal Officer September 18, 2026 Sell 314 $38.70 $12,152
Satchi-Fainaro Ronit Director August 21, 2026 Sell 415 $37.25 $15,459
Weiss Amir Chief Accounting Officer August 21, 2026 Sell 6,945 $37.61 $261,201
Weiss Amir Chief Accounting Officer August 21, 2026 Sell 2,500 $37.63 $94,075
Lippman Evan EVP, Business Development August 17, 2026 Sell pre-set plan 18,600 $36.57 $680,202
Zaks Tal Zvi Director August 5, 2026 Sell 17 $34.87 $593
Hughes Eric A See "Remarks" August 3, 2026 Sell pre-set plan 25,578 $34.88 $892,161
Jover Placid See "Remarks" August 3, 2026 Sell pre-set plan 12,827 $34.88 $447,406
Shields Matthew EVP, Global Operations June 18, 2026 Sell 9,989 $32.19 $321,546

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Trades by members of Congress

All 13 trades and filings

No trades in Teva Pharmaceutical Industries LTD disclosed in the last 12 months; 13 earlier trades on record.

  • Greg Gianforte(MT):Purchase, $15,001 - $50,000, traded November 13, 2020, filed December 2, 2020
  • Donna Shalala(FL):Sale (full), $1,001 - $15,000, traded May 7, 2020, filed May 15, 2020
  • David E. Price(D-NC 4):Sale (full), $1,001 - $15,000, traded June 19, 2019, filed July 11, 2019

Value ranges as filed; reports can arrive up to 45 days after a trade.

Earnings dates and SEC filings

Results announcements

Next expected around January 27, 2027 estimated from the company's past filing pattern, not announced

  • November 3, 2026
  • July 29, 2026
  • April 29, 2026
  • January 28, 2026
  • January 12, 2026
  • November 5, 2025

Recent SEC filings

Data status

When each part of this page on Teva Pharmaceutical Industries LTD was last updated.

DataLast updatedSource
Share priceExchange closing prices
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Teva Pharmaceutical Industries LTD in brief

What does Teva Pharmaceutical Industries LTD do?
Teva Pharmaceutical Industries LTD is a US-listed company in the pharmaceuticals industry. Its financial year ends in December.
What is Teva Pharmaceutical Industries LTD's stock ticker?
Teva Pharmaceutical Industries LTD trades under the ticker TEVA on NYSE. This page brings together its financial statements, valuation models, ownership and recent company updates.
Who are Teva Pharmaceutical Industries LTD's largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Blackrock, Inc., Harel Insurance Investments & Financial Services Ltd. and Phoenix Financial Ltd. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
Are insiders buying or selling Teva Pharmaceutical Industries LTD stock?
Over the last 12 months, Teva Pharmaceutical Industries LTD's directors and officers reported 0 open-market purchases and 58 sales on Form 4. The insider trading page charts every trade.
When is Teva Pharmaceutical Industries LTD's next earnings date?
Around November 3, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Teva Pharmaceutical Industries LTD announces its own schedule.